Reduced thrombogenicity of nitinol stents—In vitro evaluation of different surface modifications and coatings
Source abstract
Abstract
The material and the surface patterns of intravascular stents play a pivotal role in activating platelets and triggering adherence of inflammatory cells that consecutively leads to renarrowing caused by neointimal hyperplasia. To improve these features, besides mechanical and chemical modifications, ways of masking the stent by covering have been developed. In addition, polymer-coated stents are used as vehicle for local drug delivery. But as substances used for this application are described to possess an inflammatory potential, this aspect has to be evaluated. In the present study we compared different approaches to surface alterations applied to a nitinol stent design. Besides commonly used techniques like passivation and electropolishing, we evaluated coatings with heparin, aluminium and a polyurethane polymer regarding their thrombogenic and inflammatory characteristics. By weaving thin elastomer fibres a graft was generated. The previously described Chandler loop was used to simulate arterial flow conditions ex vivo using rotating PVC tubings filled with human blood. All stents received 120 min of blood contact. To determine thrombocyte activation and inflammatory reaction, the platelet count and levels of beta-TG, TAT and PMN-elastase were assessed. Scanning electron microscopy was used to visualize the reactions. Mechanical polishing and passivation did not improve the stent surface characteristics while sandblasting, electropolishing and aluminium covering decreased activation of the coagulation cascade. In terms of thrombogenicity, the heparin coating had no beneficial effect. The lowest thrombogenic potential was found in the Polyurethane-coated stent group. All stents showed similar levels of polymorph nuclear granulocyte elastase except for the membrane design. While mechanical and chemical modifications are able to reduce thrombogenicity, coating with this particular polyurethane polymer seems to be superior to these approaches regarding the parameters assessed in this experimental setting. The Chandler loop is a valuable tool to test polymeric coatings ex vivo since these modifications may reduce drug performance by inducing inflammatory reaction themselves.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Coronary Interventions and Diagnostics · Antiplatelet Therapy and Cardiovascular Diseases · Platelet Disorders and Treatments
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (25)
Show source-provided references
1. Pathophysiology of coronary artery restenosis
2. Inflammation and restenosis in the stent era10.1161/01.ATV.0000037100.44766.5B ↗
3. Thrombogenicity of various endovascular stent types: an in vitro evaluation10.1016/S1051-0443(07)61868-5 ↗
4. Effect of modification of oxide layer on NiTi stent corrosion resistance10.1002/(SICI)1097-4636(199824)43:4<433::AID-JBM11>3.0.CO;2-# ↗
5. Heparin-coated coronary stents
6. Polydimethylsiloxane/polyether-mixed macrodiol-based polyurethane elastomers: biostability10.1016/S0142-9612(99)00271-9 ↗
7. Designing biostable polyurethane elastomers for biomedical implants10.1071/CH02168 ↗
8. Long-term in vivo biostability of poly(dimethylsiloxane)/poly(hexamethylene oxide) mixed macrodiol-based polyurethane elastomers10.1016/j.biomaterials.2004.01.004 ↗
9. Platelets and restenosis10.1016/S0735-1097(99)00596-3 ↗
10. Heparin coating of the stent graft effects on platelets, coagulation and complement activation10.1016/S0142-9612(00)00190-3 ↗
11. Ticlopidine pretreatment before coronary stenting is associated with sustained decrease in adverse cardiac events: data from the evaluation of platelet IIb/IIIa inhibitor for stenting (EPISTENT) trial10.1161/01.CIR.103.10.1403 ↗
12. The use of the glycoprotein IIb/IIIa receptor antagonists during percutaneous coronary intervention10.1111/j.1540-8183.2002.tb01036.x ↗
13. Nitinol versus stainless steel stents: acute thrombogenicity study in an ex vivo porcine model10.1016/S0142-9612(02)00030-3 ↗
14. Metallic surface modification
15. Reduction in thrombotic events with heparin-coated Palmaz-Schatz stents in normal porcine coronary arteries10.1161/01.CIR.93.3.423 ↗
16. Randomised comparison of implantation of heparin-coated stents with balloon angioplasty in selected patients with coronary artery disease (Benestent II)10.1016/S0140-6736(97)11128-X ↗
17. Platelet activation after stenting with heparin-coated versus noncoated stents10.1016/S0002-8703(03)00317-X ↗
18. Heparin-coated stent placement for the treatment of stenoses in small coronary arteries of symptomatic patients10.1161/01.CIR.0000053442.64637.34 ↗
19. Segmented polyurethane: a new elastomer for biomedical applications10.1126/science.158.3807.1481 ↗
20. A review of the biostability and carcinogenicity of polyurethanes in medicine and the new generation of ‘biostable’ polyurethanes10.1163/156856294X00347 ↗
21. Marked inflammatory sequelae to implantation of biodegradable and nonbiodegradable polymers in porcine coronary arteries10.1161/01.CIR.94.7.1690 ↗
22. Granulomatous ‘foreign body reactions’ contribute to exaggerated in-stent restenosis10.1097/00019501-199901000-00002 ↗
23. Biologic fixation of polyester-versus polyurethane-covered stents in a porcine model10.1016/S1051-0443(07)61654-6 ↗
24. Macrophage behavior on surface-modified polyurethanes10.1163/156856204323046843 ↗
25. Perivascular inflammation after balloon angioplasty of porcine coronary arteries10.1161/hc4301.097195 ↗